Epcoritamab (Epcor) Plus Lenalidomide - (EPCORE DLBCL-4)

October 5, 2026: Genmab (NASDAQ: GMAB) and AbbVie (NYSE: ABBV) reported positive topline Phase 3 results from EPCORE DLBCL-2 (NCT05578976) evaluating subcutaneous epcoritamab plus R-CHOP versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma/large B-cell lymphoma patients with IPI 2-5. The study showed a statistically significant and clinically meaningful progression-free survival benefit; in the primary endpoint population (IPI 3-5), risk of progression or death was reduced by 51% (HR 0.49, 95% CI 0.35-0.69; p<0.0001). The release also cites a 51% reduction in progression or death in DLBCL patients with IPI 2-5 (HR 0.49, 95% CI 0.36-0.67; p<0.0001). Safety was described as generally well tolerated and consistent with known profiles of epcoritamab and R-CHOP.

The ongoing global open-label trial randomized patients 2:1 to six cycles of epcoritamab plus R-CHOP followed by two cycles of epcoritamab, or six cycles of R-CHOP followed by two cycles of rituximab. Genmab and AbbVie said they will engage global regulatory authorities on next steps, and data will be submitted for presentation at a future medical meeting. The combination remains investigational and is not approved by regulators.